Episodes 181-195 of 256
Pacritinib for Myelofibrosis Across the Cytopenic Spectrum
MinuteCE®Pacritinib for Myelofibrosis Across the Cytopenic Spectrum
Advancements in GU Cancers: Key Data from AUA 2024
CME/CEAdvancements in GU Cancers: Key Data from AUA 2024
Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma
Project Oncology®Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma
- advertisement
Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGFInhibitors
MinuteCE®Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGFInhibitors
Pivotal Data Supporting First-Line Durvalumab/Tremelimumab in Unresectable HCC
MinuteCE®Pivotal Data Supporting First-Line Durvalumab/Tremelimumab in Unresectable HCC
Managing Adverse Events Associated With ICI Combinations in Patients With Unresectable HCC
MinuteCE®Managing Adverse Events Associated With ICI Combinations in Patients With Unresectable HCC
Case by Case: Optimizing Dual Immune Checkpoint Inhibitor Combination Therapies in Advanced Driver-Negative Non–Small Cell Lung Cancer
CME/CECase by Case: Optimizing Dual Immune Checkpoint Inhibitor Combination Therapies in Advanced Driver-Negative Non–Small Cell Lung Cancer
Empowering Treatment Choice: The Essential Role of Shared Decision-Making in Unresectable HCC
MinuteCE®Empowering Treatment Choice: The Essential Role of Shared Decision-Making in Unresectable HCC
- advertisement
Current Unmet Needs in the Field of Unresectable HCC
MinuteCE®Current Unmet Needs in the Field of Unresectable HCC
Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models
MinuteCE®Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models
Use of ICI Combination Regimens in Patients With Intermediate-Stage HCC
MinuteCE®Use of ICI Combination Regimens in Patients With Intermediate-Stage HCC
